Use of 3-D Printers for the Production of Medical Devices (R41/R42)

The summary for the Use of 3-D Printers for the Production of Medical Devices (R41/R42) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Use of 3-D Printers for the Production of Medical Devices (R41/R42): This funding opportunity announcement (FOA) invites Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to propose research to support research to develop 3D printers, polymers, and process specifications to produce premature- and neonatal-specific devices for external use or short-term insertion and implantation into the human body.

Medical devices for premature infants and neonates are often not available in appropriate sizes. As a result, pediatric-sized devices have to be used and the sizing mismatch sometimes leads to deleterious consequences. Medical device companies find it difficult economically to produce the small quantities of devices for this patient population.

3D printing provides a potential solution to this problem as they can produce mechanically complex, patient-matched components with short lead times. Research is currently underway to create commercially viable printers capable of producing bioresorbable scaffolds with implanted stem cells for construction of new tissues and organs. However, no companies are currently supplying 3D printers and materials that can produce flexible implantable medical devices. If such systems were available, health care providers could provide better care to premature infant and neonatal patients.

Federal Grant Title:	Use of 3-D Printers for the Production of Medical Devices (R41/R42)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HD-15-024
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Child Health and Human Development Extramural Research
Current Application Deadline:	Feb 10, 2015
Original Application Deadline:	Feb 10, 2015
Posted Date:	Dec 9, 2014
Creation Date:	Dec 10, 2014
Archive Date:	Mar 13, 2015
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$150,000
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;

Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;

SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR

SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR

SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.

Has, including its affiliates, not more than 500 employees.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-15-024.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...; • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...; • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...; • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed); • Biological Testing Facility (X01 Clinical Trial Not Allowed); • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...